Conditions: Advanced Cancer
Keywords: metastatic solid tumors Malignant/M-Neoplasm Pancreas NOS Absorption Distribution Metabolism Excretion Mass balance Metabolic profile Radiolabeled study
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 3
Healthy volunteers: no

Brief summary:
This is an open-label study being conducted to determine the metabolism and physiological disposition of radiolabeled LY2603618 after a single dose in patients with advanced and/or metastatic solid tumors.

After a minimum 7-day washout period following the carbon-14-labeled LY2603618 (\[\^14C\]LY2603618) dose, patients will be allowed to continue to receive continued access to LY2603618 in combination with pemetrexed or gemcitabine as outpatients.

Detailed description:

Arms:
arm 1: Single 250 milligram (mg) intravenous dose of LY2603618 containing carbon-14-labeled LY2603618 (\[\^14C\]LY2603618).

After the completion of a minimum 7-day washout period, participants may receive additional doses of LY2603618 in combination as follows:

* Gemcitabine 1000 milligrams per square meter (mg/m\^2) on Days 1, 8, and 15 with 230 mg LY2603618 being administered on Days 2, 9 and 16 of a 28-day cycle OR
* Pemetrexed 500 mg/m\^2 on Day 1 and 275 mg LY2603618 on Day 2 of a 21-day cycle

Participants will be allowed to continue to receive the combination therapy until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression.

Interventions: intervention 1: LY2603618 intervention 2: Pemetrexed intervention 3: Gemcitabine
Intervention descriptions: intervention 1: Administered intravenously intervention 2: Administered intravenously intervention 3: Administered intravenously

Protocol document: